searchDoxazosinSystematic (IUPAC) name[4-(4-amino-6,7-dimethoxy- quinazolin-2-yl) piperazin-1-yl]- (2,5-dioxabicyclo[4.4.0] deca-6,8,10-trien-4-yl) methanoneIdentifiersCAS number 74191-85-8ATC code C02CA04PubChem 3157DrugBank doxazosin mesylate mg 596 dataFormula C23H25N5O5Mol. mass 451.475 g/molPharmacokinetic.

a sustained release form of doxazosin, to be marketed as Cardura® XL.It is an alpha blocker used to treat high blood pressure and benign prostatic hyperplasia.On February 22, 2005, the US FDA approved a sustained release form of doxazosin mesylate mg 596 to be marketed as Cardura® XL.It doxazosin mesylate mg 596 an alpha blocker used to treat high blood pressure and benign prostatic hyperplasia.On February 22, 2005, doxazosin mesylate mg 596 US FDA approved a sustained release form of doxazosin, to be marketed as Cardura® XL.It is an alpha blocker used to treat high blood pressure and benign prostatic hyperplasia.On February 22, 2005, the US FDA approved a sustained release form of doxazosin, to be marketed as Cardura® XL.It is an doxazosin mesylate mg 596 adrenergic receptor blocker which doxazosin mesylate mg 596 doxazosin mesylate mg 596 binding of doxazosin mesylate mg 596 to alpha receptors in the autonomic nervous system. The primary doxazosin mesylate mg 596 of this blockage is relaxed vascular smooth muscle tone (vasodilation), which decreases peripheral vascular resistance, leading to doxazosin mesylate mg 596 blood pressure.[edit] External links.

to treat high blood pressure and benign prostatic hyperplasia.On February 22, doxazosin mesylate mg 596 the US FDA approved a sustained.